Researchers at Harvard Medical School have found that blocking the neuron-released peptide CGRP decreases pain sensitivity and reduces lesion size in endometriosis. Endometriosis is a painful, steroid-dependent inflammatory condition in which tissue similar to that of the endometrial lining grows and establishes outside the uterine mucosa. Read More

Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at the World ADC 2024 conference in San Diego Nov. 6, with plans to move the assets into clinical trials. Poster presentations of both ADC candidates “drew significant attention from the attendees” at the oncology meeting, Incheon, South Korea-based Celltrion said, while highlighting its efforts to transition from a biosimilar maker to a novel therapy developer. Read More

Researchers from Adipo Therapeutics LLC presented data from preclinical studies that aimed to assess the γ-secretase inhibitor ADPO-002 (dibenzazepine) for the treatment of obesity. Read More

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion protein BCR-ABL1. The first-generation ABL tyrosine kinase inhibitor (TKI) Gleevec (imatinib) has significantly enhanced the prognosis of CML patients. Read More

Aditum Bio Management Company LLC and Nanjing Leads Biolabs Co. Ltd. have announced the creation of Oblenio Bio. Read More

Basal-like breast cancer is a very aggressive subtype of breast cancer with a poor prognosis. Read More

Cannabinoid receptor type 1 (CB1) blockers have been shown to attenuate diet-induced obesity. Read More

Oregon Health and Science University (OHSU) and the Southern Research Institute have patented compounds reported to be useful for the treatment of alphaviral infections. Read More

Glioblastoma is the most aggressive adult brain cancer, with a 5-year survival rate of 5%. Read More

Voronoi Inc. has discovered EGFR (Leu858Arg/Thr790Met/Cys797Ser triple mutant) and EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors. Read More

Although antifibrotic agents can contribute to suppressing renal function decline when administered in combination with existing treatments for chronic kidney disease, drugs targeting kidney fibrosis have yet to reach the clinic. Read More

Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment of cancer. Read More

Retinitis pigmentosa (RP) is the most common hereditary degenerative eye disease that leads to progressive vision loss, primarily caused by retinal degeneration. Read More

The University of Wisconsin-Madison has synthesized a next-generation prostate-specific member antigen (PSMA)-targeting small molecule, ART-101, for the treatment of advanced prostate cancer. Read More

Pfizer Inc. has presented compounds targeting GTPase KRAS and its mutant forms reported to be useful for the treatment of cancer. Read More

Nodus Oncology Ltd. presented the discovery of NODX-010, a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor being developed for the potential treatment of cancer, including tumors resistant to PARP inhibitors. Read More

Researchers from Duality Biologics (Suzhou) Co. Ltd. presented the discovery and preclinical characterization of DB-1314, a novel delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC) for the treatment of cancer. Read More

Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder. Read More

Additional early-stage research and drug discovery news in brief, from: Alterity Therapeutics, Mozart Therapeutics, Theradaptive. Read More